Pneumococcal conjugate vaccines (PCVs) are safe and effective for reducing illness and deaths caused by Streptococcus pneumoniae (1) . Recommendations for PCV use from the World Health Organization (WHO) (1, 2) and funding from the GAVI Alliance have resulted in an increase in PCV introductions into national immunization programs, especially in lower-income countries. Additionally, new formulations that cover more serotypes commonly causing disease in lower-and middle-income countries have become available. This report uses WHO data from 2000-2012, stratified by country disease burden characteristics and World Bank country income groups, to describe global progress in PCV introduction. As of December 2012, a total of 86 (44%) WHO member states have added PCV to the routine infant immunization schedule of their national immunization programs; among those, 23 have introduced PCV with GAVI Alliance support. PCV introduction among WHO member states was most common in the Americas Region (60% of member states), followed by the Eastern Mediterranean Region (50%), European Region (49%), African Region (41%), and Western Pacific Region (33%); none of 11 WHO member states in the South-East Asia Region have introduced PCV. Proportions of low-and middle-income countries with PCV introductions were similar. The proportion of the world's birth cohort living in countries with PCV in national immunization programs increased from 1% in 2000 to 31% in 2012. These findings suggest that efforts to increase PCV introduction and use globally are succeeding; however, gaps in PCV use remain in Asia and countries with large birth cohorts, where concerted efforts should be focused.
Worldwide, an estimated 14.5 million episodes of serious pneumococcal disease (including pneumonia, meningitis, and sepsis) occur each year in children aged <5 years, resulting in approximately 500,000 deaths, almost all of which occur in low-and middle-income countries (3). PCV was first licensed in 2000 as a formulation that provided protection against seven of the most common pneumococcal serotypes. In 2006, WHO recommended that PCV be included in all routine immunization programs, especially in countries with high pneumococcal disease burden, defined as >10% of deaths in children aged <5 years attributed to pneumonia or pneumonia mortality rate of >50 deaths per 1,000 live births among children aged <5 years (1) . Beginning in 2010, new PCV formulations protecting against 10 and 13 serotypes have become available for use, offering better coverage for serotypes commonly causing disease in low-and middle-income countries (4).
To assess the status of global PCV introduction, a WHO database tracking vaccine introductions was used to identify countries that included PCV in routine infant immunization schedules as of December 2012. PCV introductions were characterized by WHO region (5), eligibility for GAVI Alliance financial support,* World Bank income classification, † and pneumonia disease burden (6) . The proportion of the global birth cohort living in countries that had introduced PCV was calculated using United Nations 2010 birth cohort estimates (6) . using PCV, coverage with 3 doses of PCV assessed at age 12-24 months was highest among high-and low-income countries (median: 92% and 95%, respectively); less among upper-middle income countries (median: 76%), and lowest among lower-middle income countries (median: 44%) (Table) .
Reports from 11 postintroduction evaluations conducted during 2010-2012 in low-and middle-income African countries described programmatic issues related to PCV introductions. First, programs need accurate data to define target populations, accompanied by clear messages to health workers and the community to prioritize target populations. In several countries, children outside the target infant age group also were brought for vaccination and, in most cases, were vaccinated, creating shortages of PCV for the target age group. Second, health worker knowledge that PCV provides protection against only one cause of pneumonia was crucial to ensure that they educated caretakers about other options for prevention and treatment of pneumonia. Third, weaknesses were identified in the underlying capacity of the immunization systems, including needs for 1) innovative training approaches to address the complexity of messages relating to use of new vaccines, 2) improvement of supportive supervision, and 3) further enhancement of injection safety, injection waste management, and monitoring of adverse events after immunization. 
Editorial Note
Use of PCV has increased substantially since 2000, especially in low-and middle-income countries, where the burden of pneumococcal disease and deaths is high. A critical factor enabling vaccine introductions in low-income countries has been support from the GAVI Alliance. As of the first quarter of 2013, 24 countries have introduced PCV with GAVI Alliance support, and 27 additional countries have been approved for GAVI Alliance-supported PCV introductions (7). However, important gaps in PCV introduction remain, notably in the WHO South-East Asia Region and in countries with large birth cohorts. The lack of PCV introduction in several large countries is reflected in the gap between the proportion of countries having introduced PCV (44%) and the proportion of the world's birth cohort living in countries that have introduced PCV (31%). Low-and middle-income countries lagged behind high-income countries, with all low-income introductions attributed to GAVI Alliance support. Middleincome countries are not eligible for GAVI Alliance support and need to weigh vaccine procurement and operational costs against costs of other health priorities. Additionally, only two companies (Pfizer and GlaxoSmithKline) manufacture any of the three PCV formulations; each formulation is supplied by one company and insufficient supply has led to delays in planned introductions in some countries. Although pneumonia is a leading killer of children in the majority of countries, the disease burden preventable by PCV might be unrecognized, decreasing local demand for the vaccine. Improved data on the impact of PCV vaccination in reducing and preventing disease caused by Streptococcus pneumoniae will help guide policy decisions about PCV introduction and sustained use (1) .
The findings of this report are subject to at least two limitations. First, the vaccination coverage estimates might differ from actual coverage because of inaccurate reporting of target population size or number of doses administered. Additionally, coverage estimates were only from countries using PCV for at least 2 years and might not be reflective of coverage achieved in all settings.
In spite of these challenges, the rate at which PCV has been introduced into childhood immunization programs worldwide has been faster than that of other new vaccines in the past (8) . In addition to WHO recommendations and GAVI Alliance support, other measures are encouraging PCV use around the world. WHO and UNICEF promote PCV use in the integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD) as a comprehensive approach to reducing pneumonia morbidity and mortality and as an important strategy for achieving United Nations Millennium Development Goal 4 to reduce child mortality (9) . Further information on the magnitude of PCV benefits in low-and middle-income countries might encourage more policy makers to introduce PCV into immunization programs; studies are ongoing and data on the impact and effectiveness of PCV in reducing disease caused by Streptococcus pneumoniae in these settings is being prepared for publication. A WHO manual for measuring the impact of the Haemophilus influenzae type b conjugate vaccine and PCV can assist with designing studies to determine how PCV performs in a variety of settings. § The progress of PCV introductions noted in this report and anticipated PCV introductions in coming years will help reduce the burden of pneumonia and pneumococcal disease worldwide.
What is already known on this topic?
Globally, Streptococcus pneumoniae is a significant cause of pneumonia, meningitis, and sepsis in children aged <5 years and leads to an estimated 14.5 million episodes of serious disease and approximately 500,000 deaths annually. Pneumococcal conjugate vaccines (PCVs) are safe and effective for prevention of this disease, and the World Health Organization (WHO) recommends that PCV be included in all routine immunization programs.
What is added by this report?
PCV use increased from one (1%) WHO member state in 2000 to 86 (44%) in 2012. Gaps in PCV introductions were noted in Asia and in countries with large birth cohorts; only 31% of the world's birth cohort currently has access to PCV. WHO recommendations for use, financial support through the GAVI Alliance for PCV introduction in lower-income countries, and newer PCV formulations that protect against additional serotypes likely contributed to the increased use of PCV.
What are the implications for public health practice?
Increased use of PCV will help reduce the incidence of pneumonia and pneumococcal disease worldwide. The success of PCV introductions and the lessons learned from countries that have added PCV to their immunization programs will help guide decisions about future PCV introductions and sustained use.
